A Trial Using Double-Bolus THR-100 Versus Streptokinase
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This novel fibrinolytic agent is a 136 amino acid single chain protein secreted by some
strains of Staphylococcus aureus and readily produced by recombinant DNA technology. Two
natural variants of recombinant staphylokinase, THR-100 and SakSTAR, have been developed for
investigational use in preliminary trials. Like SK, it forms an equimolar complex with
plasmin which in turn activates plasminogen to plasmin. Unlike SK, the complexed, activated
molecule (which undergoes proteolytic cleavage of the first ten amino acids to generate
active staphylokinase) has a high degree of fibrin-selectivity in a human plasma milieu. This
fibrin-selectivity is due in large measure to potent activation at the clot surface by trace
amounts of plasmin, and rapid inactivation of the circulating complex by antiplasmin. Hence,
it provides an interesting and promising alternative therapy.